In acute myeloid leukemia (AML) patients there is higher expression of the GSL lactotriaosylceramide (Lc3), GM3, and neolactotetraosylceramide (nLc4) in the bone marrow compared to healthy donors. Here, CTSA is linked to acute myeloid leukemia.